



The Role of TOP2B and DNA Damage/Repair in Cancer

Guest Editor:

Dr. Jonathan B. Coulter

Department of Urology, The
Johns Hopkins University School
of Medicine, Baltimore, MD, USA

Deadline for manuscript
submissions:

closed (10 December 2020)

Message from the Guest Editor

Accumulating evidence demonstrating that transcriptional programs require the class II topoisomerase TOP2B and DNA damage and repair factors challenges the simplified view of these programs support one involving large-scale genomic reorganization. Importantly, DNA damage mediated by TOP2B seems to represent a vulnerability for cancer cells and a better mechanistic understanding of these processes may lead to effective cancer prevention and treatment strategies.

TOP2B has been shown to be involved in androgen-induced genomic rearrangements, yet the mechanisms through which TOP2B-mediated DNA double strand breaks occur have not yet been elucidated. In this Special Issue, we aim to highlight recent advances in understanding TOP2B-mediated DNA damage and repair with respect to cancer biology, treatment paradigms, carcinogenesis, and personalized medicine.

We invite the submission of original articles to this Special Issue that aim to uncover insights into the role of TOP2B in DNA damage and repair in cancers. We welcome studies ranging from mechanistic insights and innovative techniques to novel cancer treatment strategies.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA

2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)